Skip to content
Pharma Observatory a Scientist.com platform

Organization (Industry)

Mirati Therapeutics (United States)

ClinicalTrials.gov lists Mirati Therapeutics (United States) as lead sponsor of 51 trials. It has 85 active development programs and 27 approved assets.

US Industry
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

11 0 2004 2027

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 2 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 3 in 2026 and about 2 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

This page covers Mirati Therapeutics (United States): 51 lead-sponsored trials and 1 legal-entity registration. Part of BRISTOL MYERS SQUIBB CO.

Get the Mirati Therapeutics (United States) report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (38)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Lung Neoplasms 24
Carcinoma, Non-Small-Cell Lung 22
Neoplasm Metastasis 12
Colorectal Neoplasms 9
Colonic Neoplasms 7

Trials by start year as sponsor or collaborator (21)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 2
2025 2
2024 3
2023 11
2022 9
2021 9
2020 5
2019 3
2018 3
2017 2

Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (85)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
Adagrasib Lung Neoplasms Phase 3 7
Adagrasib Carcinoma, Non-Small-Cell Lung Phase 3 7
Adagrasib Neoplasm Metastasis Phase 3 6
PEMBROLIZUMAB Carcinoma, Non-Small-Cell Lung Phase 3 3
PEMBROLIZUMAB Lung Neoplasms Phase 3 3

Approved assets (27)

Shown in this order: max phase first.

Approved assets
Drug Trials
Adagrasib 15
NIVOLUMAB 7
PEMBROLIZUMAB 7
DOCETAXEL 3
CETUXIMAB 3

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
44% hit target (n=25) 42% on time (n=26)

Journals published in (19)

Shown in this order: most published in first.

Journals published in
Journal Publications
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 3
The New England journal of medicine 3
Investigational new drugs 2
Targeted oncology 2
Annals of oncology : official journal of the European Society for Medical Oncology 1

US granted patents (1)

Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.

US granted patents
US patents granted Granted in the last 5 years Most recent grant
39 30 2025-12-02

Organization relationships (9)

Shown in this order: most evidence first.

Organization relationships
Related organization Relationship Evidence
UCLA Health Co sponsors trial with 1
University of Birmingham Co sponsors trial with 1
Cancer Research UK Co sponsors trial with 1
Grupo Español Multidisciplinar de Melanoma Co sponsors trial with 1
ETOP IBCSG Partners Foundation Co sponsors trial with 1

Latest dated events (113)

Shown in this order: newest first.

Latest dated events
Date Event Source
2026-08-05 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-05-06 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2025-12-02 Patent granted Granted US patents (PatentsView / USPTO)
2025-11-11 Patent granted Granted US patents (PatentsView / USPTO)
2025-09-23 Patent granted Granted US patents (PatentsView / USPTO)

Biomarker capability evidence (267)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
ATP12A Trial collaborator Named in trial inclusion criteria
ATP4A Trial collaborator Named in trial inclusion criteria
AXL Trial sponsor Named in trial inclusion criteria
BRAF Trial sponsor Named in trial inclusion criteria
BRAF Trial collaborator Named in trial inclusion criteria

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.